{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T06:26:55Z","timestamp":1766557615632,"version":"build-2065373602"},"reference-count":53,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.vaccine.2023.10.025","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T07:59:42Z","timestamp":1698220782000},"page":"6922-6929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Background rates for severe cutaneous reactions in the US: Contextual support for safety assessment of COVID-19 vaccines and novel biologics"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1877-7419","authenticated-orcid":false,"given":"Diane","family":"Gubernot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail","family":"Menis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbee","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9707","key":"10.1016\/j.vaccine.2023.10.025_b0005","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","article-title":"Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines","volume":"374","author":"Black","year":"2009","journal-title":"Lancet"},{"issue":"28","key":"10.1016\/j.vaccine.2023.10.025_b0010","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1016\/j.vaccine.2021.05.016","article-title":"U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines","volume":"39","author":"Gubernot","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.10.025_b0015","unstructured":"World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. https:\/\/covid19.who.int; 2022 [accessed 5 January 2023]."},{"issue":"9","key":"10.1016\/j.vaccine.2023.10.025_b0020","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/ijd.14409","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience","volume":"58","author":"Zhang","year":"2019","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.vaccine.2023.10.025_b0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00006454-200102000-00022","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system","volume":"20","author":"Ball","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2023.10.025_b0030","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson Syndrome and toxic epidermal necrolysis in Untied States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.025_b0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archderm.1990.01670250049006","article-title":"The incidence of erythema multiforme, Stevens-Johnson Syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients","volume":"126","author":"Chan","year":"1990","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.vaccine.2023.10.025_b0040","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/sim.4780100408","article-title":"Using a claims database to investigate drug-induced Stevens-Johnson syndrome","volume":"10","author":"Strom","year":"1991","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2023.10.025_b0045","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson Syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.vaccine.2023.10.025_b0050","first-page":"1039","article-title":"Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981\u20131985","volume":"23","author":"Roujeau","year":"1990","journal-title":"Arch Dermatol"},{"issue":"7","key":"10.1016\/j.vaccine.2023.10.025_b0055","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990\u20131992): structure and results of a population-based registry","volume":"49","author":"Rzany","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2023.10.025_b0060","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1001\/archderm.1991.01680050083008","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany","volume":"127","author":"Schopf","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.vaccine.2023.10.025_b0065","unstructured":"WHO website. International Classification of Diseases webpage. List of Official ICD-10 Updates. https:\/\/www.who.int\/standards\/classifications\/classification-of-diseases\/list-of-official-icd-10-updates."},{"issue":"2","key":"10.1016\/j.vaccine.2023.10.025_b0070","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/pde.12158","article-title":"The epidemiology of ophthalmologic disease associated with erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis among hospitalized children in the United States","volume":"31","author":"Moreau","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.vaccine.2023.10.025_b0075","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jaad.2016.12.024","article-title":"Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States","volume":"76","author":"Hsu","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.vaccine.2023.10.025_b0080","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/pde.13383","article-title":"Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"35","author":"Antoon","year":"2018","journal-title":"Ped Dermatol"},{"key":"10.1016\/j.vaccine.2023.10.025_b0085","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/pds.3778","article-title":"Asgan. Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases","volume":"24","author":"Davis","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2023.10.025_b0090","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1097\/ICO.0000000000000646","article-title":"Incidence of Stevens-Johnson Syndrome and chemical burns to the eye","volume":"34","author":"White","year":"2015","journal-title":"Cornea"},{"issue":"2","key":"10.1016\/j.vaccine.2023.10.025_b0095","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/pde.13050","article-title":"Nationwide survey of Stevens-Johnson Syndrome and toxic epidermal necrolysis in children in the United States","volume":"34","author":"Okubo","year":"2017","journal-title":"Ped Dermatol"},{"issue":"10","key":"10.1016\/j.vaccine.2023.10.025_b0100","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.284.10.1271","article-title":"Postlicensure safety surveillance for varicella vaccine","volume":"284","author":"Wise","year":"2000","journal-title":"J Am Med Assoc"},{"issue":"7-8","key":"10.1016\/j.vaccine.2023.10.025_b0105","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0264-410X(00)00297-8","article-title":"The postmarketing safety profile of varicella vaccine","volume":"19","author":"Sharrar","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.10.025_b0110","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.vaccine.2019.12.028","article-title":"Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999\u20132017","volume":"38","author":"Su","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.10.025_b0115","unstructured":"ACAM2000, Smallpox (Vaccinia) Vaccine, Live. Package Insert. Available at: https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package-Insert---ACAM2000.pdf."},{"issue":"6","key":"10.1016\/j.vaccine.2023.10.025_b0120","doi-asserted-by":"crossref","first-page":"e15153","DOI":"10.1111\/dth.15153","article-title":"Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: an observational study","volume":"34","author":"Grieco","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.vaccine.2023.10.025_b0125","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.025_b0130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaad.2021.09.002","article-title":"Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry-based study","volume":"86","author":"McMahon","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.vaccine.2023.10.025_b0135","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/j.jaad.2021.11.016","article-title":"Skin reactions to COVID-19 vaccines: an American Academy of Dermatology\/International League of Dermatological Societies registry update on reaction location and COVID vaccine type","volume":"86","author":"Freeman","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.025_b0140","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12903-022-02124-2","article-title":"Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases","volume":"22","author":"Petruzzi","year":"2022","journal-title":"BMC Oral Health"},{"key":"10.1016\/j.vaccine.2023.10.025_b0145","first-page":"1","article-title":"Case of atypical erythema multiforme following coronavirus disease 2019 vaccination","volume":"00","author":"Iwasawa","year":"2021","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.025_b0150","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1111\/jdv.17682","article-title":"Pfizer-BioNTech SARS-CoV-2 mRNA vaccine-associated erythema multiforme","volume":"36","author":"Borg","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.vaccine.2023.10.025_b0155","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/ced.14714","article-title":"A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer\u2013BioNTech) COVID-19 vaccine","volume":"46","author":"Lavery","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"10.1016\/j.vaccine.2023.10.025_b0160","doi-asserted-by":"crossref","DOI":"10.1111\/ijd.15894","article-title":"Atypical erythema multiforme related to BNT162b2 (Pfizer\u2013BioNTech) COVID\u201019 vaccine","volume":"60","author":"Buj\u00e1n Bonino","year":"2021","journal-title":"Int J Dermatology"},{"key":"10.1016\/j.vaccine.2023.10.025_b0165","first-page":"104461","article-title":"Severe erythema multiforme post-COVID-19 moderna vaccine: case report and literature review","author":"Fadul","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.vaccine.2023.10.025_b0170","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jdcr.2021.12.002","article-title":"Erythema multiforme reactions after Pfizer\/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccination: a case series","volume":"32","author":"Karatas","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.vaccine.2023.10.025_b0175","doi-asserted-by":"crossref","unstructured":"Dash S,Sirka CS,Mishra S,ViswanP. COVID-19 vaccine inducedStevens-Johnson syndrome: a case report. Letter to the Editor. CEDJune 2021Available at:doi: 10.1111\/ced.14784.","DOI":"10.1111\/ced.14784"},{"issue":"4","key":"10.1016\/j.vaccine.2023.10.025_b0180","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.oooo.2021.06.019","article-title":"Stevens-Johnson syndrome post second dose of Pfizer COVID-19 vaccine: a case report","volume":"132","author":"Elboraey","year":"2021","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"4","key":"10.1016\/j.vaccine.2023.10.025_b0185","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/jocd.14756","article-title":"A case of Steven-Johnson syndrome after COVID-19 vaccination","volume":"21","author":"Mansouri","year":"2022","journal-title":"J Cosmet Dermatol"},{"issue":"8","key":"10.1016\/j.vaccine.2023.10.025_b0190","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/ijd.16222","article-title":"Stevens-Johnson syndrome precipitated by Moderna Inc. COVID-19 vaccine: a case-based review of literature comparing vaccine and drug-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"61","author":"Padniewski","year":"2022","journal-title":"Int J Dermatol"},{"issue":"8","key":"10.1016\/j.vaccine.2023.10.025_b0195","first-page":"e17215","article-title":"Toxic epidermal necrolysis post COVID-19 vaccination - first reported case","volume":"13","author":"Bakir","year":"2021","journal-title":"Cureus"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.10.025_b0200","first-page":"31","article-title":"Toxic epidermal necrolysis after COVID-19 booster vaccination: is a mixed vaccination schedule a risk?","volume":"187","author":"Jmor","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.vaccine.2023.10.025_b0205","doi-asserted-by":"crossref","first-page":"e15416","DOI":"10.1111\/dth.15416","article-title":"An extremely rare mucocutaneous adverse reaction following COVID-19 vaccination: toxic epidermal necrolysis","volume":"35","author":"Mardani","year":"2022","journal-title":"Dermatol Ther"},{"issue":"8","key":"10.1016\/j.vaccine.2023.10.025_b0210","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/jama.2021.0600","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"J Am Med Assoc"},{"issue":"10","key":"10.1016\/j.vaccine.2023.10.025_b0215","doi-asserted-by":"crossref","first-page":"e2131034","DOI":"10.1001\/jamanetworkopen.2021.31034","article-title":"Association of self-reported high-risk allergy history with allergy symptoms after COVID-19 vaccination","volume":"4","author":"Li","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.025_b0220","doi-asserted-by":"crossref","first-page":"100734","DOI":"10.1016\/j.waojou.2022.100734","article-title":"COVID-19 vaccine provocation test outcome in high-risk allergic patients: a retrospective study from a tertiary hospital in Indonesia","volume":"16","author":"Koesnoe","year":"2023","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.vaccine.2023.10.025_b0225","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40259-022-00536-8","article-title":"Other factors, such as changes in healthcare utilization during the COVID-19 pandemic, may impact reported incidence rates and these factors should be considered in future studies. Mechanisms and Management","volume":"36","author":"Luxi","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.vaccine.2023.10.025_b0230","article-title":"A case of erythema multiforme major in a patient with COVID 19: the role of corticosteroid treatment Dermatologic","author":"Demirbas","year":"2020","journal-title":"Therapy"},{"issue":"4","key":"10.1016\/j.vaccine.2023.10.025_b0235","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jaad.2020.06.1016","article-title":"The spectrum of COVID-19\u2013associated dermatologic manifestations: an international registry of 716 patients from 31 countries","volume":"83","author":"Freeman","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.vaccine.2023.10.025_b0240","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12886-021-02033-y","article-title":"Coronavirus disease 2019-associated Stevens-Johnson syndrome: a case report","volume":"21","author":"Shahraki","year":"2021","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.vaccine.2023.10.025_b0245","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/MOP.0000000000001076","article-title":"Cutaneous coronavirus disease 2019 in children: a clinical primer for diagnosis and treatment","volume":"33","author":"Dinulos","year":"2021","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.vaccine.2023.10.025_b0250","series-title":"Case Studies in Emergency Medicine","article-title":"Stevens Johnson Syndrome \u2013 \u201cSteven Who? And Why I Should Care About His Johnson?\u201d","author":"Cardon","year":"2020"},{"issue":"6","key":"10.1016\/j.vaccine.2023.10.025_b0255","first-page":"707","article-title":"Diagnosis of herpes simplex virus-induced erythema multiforme confounded by previous infection with Mycoplasma pneumonia","volume":"12","author":"Ladizinski","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.vaccine.2023.10.025_b0260","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s12879-015-1154-y","article-title":"Frequency and impact of confounding by indication and healthy vaccine bias in observational studies assessing influenza vaccine effectiveness: a systematic review","volume":"15","author":"Remschimdt","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2023.10.025_b0265","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jdv.17744","article-title":"Cutaneous findings following COVID\u201019 vaccination: review of world literature and own experience","volume":"36","author":"Gambichler","year":"2022","journal-title":"Acad Dermatol Venereol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23012082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23012082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:30:06Z","timestamp":1759404606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23012082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":53,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0264410X23012082"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.10.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Background rates for severe cutaneous reactions in the US: Contextual support for safety assessment of COVID-19 vaccines and novel biologics","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}